ABVX Earnings & Financial Statements
Abivax S.A.
$87.98
+$1.76(+2.04%)
37
Overall
40
Value
18
Tech
55
Quality
Market Cap
$7.68B
Volume
1.13M
52W Range
$69.81 - $148.83
Target Price
$160.15
ABVX earnings and financial statements: Abivax S.A.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ABVX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $4.57M | $12.45M | - | - |
| Operating income | -$246.06M | -$172.98M | -$132.00M | -$55.79M |
| EBITDA | -$217.44M | -$158.15M | -$119.16M | -$75.47M |
| Net income | -$336.10M | -$176.24M | -$147.74M | -$82.98M |
| EPS (diluted) | $-4.83 | $-2.80 | $-3.43 | $-3.18 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $584.34M | $205.23M | $327.06M | $75.54M |
| Total liabilities | $129.14M | $164.64M | $131.05M | $68.36M |
| Shareholders’ equity | $455.20M | $40.58M | $196.01M | $7.19M |
| Cash and equivalents | $516.68M | $144.22M | $251.94M | $26.94M |
| Long-term debt | $554.0K | $29.06M | $2.56M | $28.46M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$161.13M | -$149.93M | -$97.13M | -$53.93M |
| Free cash flow | -$161.27M | -$150.57M | -$97.39M | -$54.26M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ABVX | $87.98 | +2.0% | 1.13M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |